Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults

IF 2.1 4区 医学 Q3 VIROLOGY Future Virology Pub Date : 2023-07-18 DOI:10.2217/fvl-2023-0069
A. Igarashi, K. Togo, Yasuhiro Kobayashi, Kazumasa Kamei, N. Yonemoto, N. Ishiwada
{"title":"Inpatient and outpatient costs associated with respiratory syncytial virus in Japanese infants and older adults","authors":"A. Igarashi, K. Togo, Yasuhiro Kobayashi, Kazumasa Kamei, N. Yonemoto, N. Ishiwada","doi":"10.2217/fvl-2023-0069","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDV-infant (n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged <1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and OAs.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fvl-2023-0069","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To evaluate healthcare resource use for respiratory syncytial virus (RSV) in Japan. Methods: Using JMDC and Medical Data Vision (MDV) claims databases, we retrospectively evaluated cost and length of hospital/intensive care unit stays in RSV-diagnosed cohorts of infants (<12 months) and older adults (OAs, ≥60 years). We analyzed the usage and costs of palivizumab in infants. Results: Mean costs among those hospitalized were $2823 (USD); $2851; and $6609 (¥131 [JPY]/$) in JMDC-infant (n = 13,752); MDV-infant (n = 22,142); and MDV-OA cohorts (n = 165), respectively. The mean cost was higher in those aged <1 month, with risk factors, and severe RSV disease. Mean cumulative cost of palivizumab prophylaxis in JMDC infant cohort was $6796/year. Conclusion: RSV causes enormous economic burden in infants and OAs.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
日本婴儿和老年人与呼吸道合胞病毒相关的住院和门诊费用
目的:评价日本呼吸道合胞病毒(RSV)医疗资源的使用情况。方法:使用JMDC和医学数据视觉(MDV)索赔数据库,我们回顾性评估了呼吸道合胞病毒诊断的婴儿(<12个月)和老年人(OAs,≥60岁)队列的住院/重症监护费用和住院时间。我们分析了帕利单抗在婴儿中的使用情况和成本。结果:住院患者的平均费用为2823美元$2851;以及6609美元(131日元/$)的JMDC婴儿(n=13752);MDV婴儿(n=22142);和MDV-OA队列(n=165)。年龄<1个月、有危险因素和严重呼吸道合胞病毒疾病的患者的平均费用更高。JMDC婴儿队列中帕利单抗预防的平均累计成本为6796美元/年。结论:呼吸道合胞病毒对婴儿和高龄产妇造成巨大的经济负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Future Virology
Future Virology 医学-病毒学
CiteScore
4.00
自引率
3.20%
发文量
84
审稿时长
6-12 weeks
期刊介绍: Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.
期刊最新文献
Trends and perspectives in tuberculosis and HIV co-infection studies over the past three decades Human RSVA-ON1, the only genotype present during 2019–2020 winter season in Riyadh, Saudi Arabia: a retrospective study Rosmarinic acid inhibits Rift Valley fever virus: in vitro, computational and analytical studies Plain language summary of the efficacy and safety of bepirovirsen in patients with chronic hepatitis B infection Expression and significance of IL-17A and IL-22 in children with infectious mononucleosis complicated with liver damage
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1